FY2027 Earnings Estimate for ESPR Issued By Zacks Research

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities research analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for Esperion Therapeutics in a research report issued to clients and investors on Tuesday, March 25th. Zacks Research analyst K. Das forecasts that the biopharmaceutical company will post earnings per share of $0.06 for the year. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

Several other equities analysts also recently issued reports on ESPR. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research report on Thursday, March 20th. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. Cantor Fitzgerald began coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price for the company. JMP Securities reaffirmed a “market outperform” rating and set a $4.00 price target (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. Finally, The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Esperion Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $6.75.

Esperion Therapeutics Stock Down 6.8 %

ESPR stock opened at $1.50 on Thursday. Esperion Therapeutics has a 52 week low of $1.47 and a 52 week high of $3.94. The stock has a market capitalization of $296.77 million, a PE ratio of -2.34 and a beta of 1.04. The firm has a 50 day moving average of $1.78 and a 200 day moving average of $2.07.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Cibc World Markets Corp purchased a new stake in Esperion Therapeutics in the 4th quarter valued at $39,000. SJS Investment Consulting Inc. acquired a new stake in shares of Esperion Therapeutics during the 4th quarter worth approximately $55,000. Crestline Management LP purchased a new stake in shares of Esperion Therapeutics during the 4th quarter valued at approximately $63,000. SLT Holdings LLC purchased a new position in Esperion Therapeutics in the fourth quarter worth approximately $66,000. Finally, Foundations Investment Advisors LLC raised its position in Esperion Therapeutics by 48.6% in the fourth quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 9,872 shares during the period. 47.39% of the stock is owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.